mantle cell lymphoma


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

mantle cell lymphoma

a clinically and biologically distinct B-cell neoplasm with a recurring acquired genetic abnormality, the t(11;14) translocation, and a heterogeneous histologic appearance that may lead to confusion with reactive or other neoplastic lymphoproliferative disorders.

mantle cell lymphoma

[man′təl]
a rare form of non-Hodgkin's lymphoma having a usually diffuse pattern. It mainly affects people over 50 years of age and runs an indolent course, although it may metastasize to the spleen or liver. See also non-Hodgkin's lymphoma.

mantle cell lymphoma

An uncommon low-to-intermediate-grade non-Hodgkin lymphoma (NHL), which is a malignancy of naive B cells. It comprises ± 6% of NHL cases in the US, slightly higher in Europe. It is hard to treat and harder to cure. It is more common in men ≥ age 55.
 
Clinical findings
Massive splenomegaly, generalised lymphadenopathy, 1/3 present with “B” symptoms—i.e., fever, weight loss, night sweats.

Sites
Nodes, spleen, bone marrow, Waldeyer's ring, GI (lymphomatous polyposis), gallbladder. 

DiffDx
• Small lymphocytic lymphoma/CLL
• MALT lymphoma
• Follicular lymphoma

Prognosis MCLs are often aggressive and involve the spleen, liver, bone marrow; they are regarded as incurable. Median 2- to 5-year survival. Cases with mutations in the immunoglobulin gene have better prognosis—40% achieve complete remission with chemotherapy.

man·tle cell lym·pho·ma

(man'tĕl sel lim-fō'mă)
A clinically and biologically distinct B-cell neoplasm with a recurring acquired genetic abnormality, the t(11;14) translocation, and a heterogeneous histologic appearance that may lead to confusion with reactive or other neoplastic lymphoproliferative disorders.
References in periodicals archive ?
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.
Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma.
Current treatment standards and emerging strategies in mantle cell lymphoma.
The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects
Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement.
Patients older than 18 years with World Health Organization (WHO) performance status <2 were eligible if they had histologically confirmed diagnosis of CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL) (grades 1 to 2), and diffuse large B-cell lymphoma (DLBCL).
By contrast, none of the patients diagnosed with either follicular lymphoma and mantle cell lymphoma was HIV positive.
Microscopically, the tissue was substantially infiltrated by an atypical lymphoid infiltrate positive for CD20, BCL2, CD5 (weakly), κ light chain and cycline D1, consistent with mantle cell lymphoma (Fig.
a division of Wyeth (NYSE: WYE), has announced that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (MCL).
VELCADE (bortezomib) for Injection, the market leader for multiple myeloma and mantle cell lymphoma patients, who have received at least one prior therapy, is the first and only marketed proteasome inhibitor.
A case report on B-cell infiltrates inherent in injection sites of a patient with leukaemic mantle cell lymphoma questioned safety of VA-E treatment in lymphomas.
A 43-year-old woman with recently diagnosed stage IV mantle cell lymphoma (MCL) presented with symptoms of night sweats, weight loss, nausea, vomiting, and left-sided abdominal pain.